OncoSil Medical Ltd (AU:OSL)
ASX:OSL
Want to see AU:OSL full AI Analyst Report?
OSL Stock Chart & Stats
AU$0.97
AU$0.00(0.00%)
At close: 4:00 PM EST
AU$0.97
AU$0.00(0.00%)
Day’s Range― - ―
52-Week RangeAU$0.37 - AU$2.08
Previous CloseN/A
Volume350.23K
Average Volume (3M)24.03K
Market Cap
AU$13.44M
Enterprise ValueAU$6.77M
Total Cash (Recent Filing)AU$2.85M
Total Debt (Recent Filing)AU$42.47K
Price to Earnings (P/E)―
Beta1.23
Next Earnings
Aug 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.95
Shares Outstanding30,888,899
10 Day Avg. Volume8,764
30 Day Avg. Volume24,029
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)4.23
Price to Sales (P/S)11.20
P/FCF Ratio-1.09
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low LeverageMinimal debt (debt-to-equity ~0.0225) gives the company balance-sheet stability and financial flexibility over the medium term. Low leverage reduces bankruptcy risk, eases ability to raise incremental financing on reasonable terms, and supports continued investment in commercialization and trials while losses persist.
Revenue GrowthSustained revenue growth (~31.8% YoY) signals increasing market adoption of the OncoSil device and validates commercial traction. For a niche medical-device company, consistent top-line growth provides a foundation to scale fixed-cost absorption, negotiate reimbursement, and justify continued clinical and commercial investment.
Specialized, High‑need ProductThe OncoSil device targets locally advanced pancreatic cancer, a high-unmet-need indication with few effective options. The therapy's procedural integration (EUS-guided implant) and focused indication create a structural niche with physician-driven adoption and potential reimbursement pathways, offering a durable competitive angle if clinical outcomes remain favorable.
Bears Say
Negative Cash FlowPersistent negative operating and free cash flows mean the company is burning cash to fund operations and commercialization. Over a multi-month horizon this creates runway pressure, increases likelihood of dilutive financing or partnership necessity, and elevates execution risk for sales, trials and regulatory activities.
Deeply Negative MarginsNegative gross, operating and net margins indicate current unit economics are not viable at scale. This suggests either high COGS, limited pricing power, or low volumes. Unless structural cost reductions, pricing improvements, or significant volume gains occur, margin deficits will impede sustainable cash generation and long-term profitability.
Very Small TeamA headcount of two implies very limited internal capacity for commercial rollout, regulatory submissions, clinical support and payer engagement. The company will likely need to hire materially or rely on external partners, which raises execution risk, extends timelines and increases near-term costs while trying to convert revenue growth into sustainable scale.
OncoSil Medical Ltd News
OSL FAQ
What was OncoSil Medical Ltd’s price range in the past 12 months?
OncoSil Medical Ltd lowest share price was AU$0.37 and its highest was AU$2.08 in the past 12 months.
What is OncoSil Medical Ltd’s market cap?
OncoSil Medical Ltd’s market cap is AU$13.44M.
When is OncoSil Medical Ltd’s upcoming earnings report date?
OncoSil Medical Ltd’s upcoming earnings report date is Aug 27, 2026 which is in 82 days.
How were OncoSil Medical Ltd’s earnings last quarter?
OncoSil Medical Ltd released its earnings results on Feb 23, 2026. The company reported -AU$0.242 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.242.
Is OncoSil Medical Ltd overvalued?
According to Wall Street analysts OncoSil Medical Ltd’s price is currently Overvalued.
Does OncoSil Medical Ltd pay dividends?
OncoSil Medical Ltd does not currently pay dividends.
What is OncoSil Medical Ltd’s EPS estimate?
OncoSil Medical Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does OncoSil Medical Ltd have?
OncoSil Medical Ltd has 30,888,899 shares outstanding.
What happened to OncoSil Medical Ltd’s price movement after its last earnings report?
OncoSil Medical Ltd reported an EPS of -AU$0.242 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 1.538%.
Which hedge fund is a major shareholder of OncoSil Medical Ltd?
Currently, no hedge funds are holding shares in AU:OSL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
OncoSil Medical Ltd Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:OSL Sentiment 93%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth AU$114.4K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
―
20 days / 200 days
Momentum
-67.40%
12-Months-Change
Fundamentals
Return on Equity
-372.27%
Trailing 12-Months
Asset Growth
-37.99%
Trailing 12-Months
Company Description
OncoSil Medical Ltd
OncoSil Medical Limited, a medical device company, focuses on the development and commercialization of localized radiation therapy for the treatment of pancreatic and distal cholangiocarcinoma in worldwide. Its lead product is OncoSil, a brachytherapy device indicated for the treatment of patients with locally advanced unresectable pancreatic cancer, in combination with gemcitabine-based chemotherapy. The company was formerly known as NeuroDiscovery Limited and changed its name to OncoSil Medical Limited in May 2013. OncoSil Medical Limited was incorporated in 2005 and is headquartered in North Sydney, Australia.
Technical Analysis
Cyclopharm Limited
―
Micro-X Ltd.
―
EMvision Medical Devices Ltd.
―
Control Bionics Ltd.
―
4DMedical Ltd
―
Options Prices
Currently, No data available
---